Investigation of the effects of herbal medicines on warfarin response in healthy subjects: A population pharmacokinetic-pharmacodynamic modeling approach

被引:61
作者
Jiang, Xuemin
Blair, Elaine Y. L.
McLachlan, Andrew J.
机构
[1] Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia
[2] Univ Chicago, Dept Med, Chicago, IL 60637 USA
[3] Concord Repatriat Gen Hosp, Ctr Evaluat & Res Ageing, Concord, Australia
[4] Sanofi Aventis, Sydney, NSW, Australia
关键词
warfarin; anticoagulants; herb-drug interactions; St John's wort; Asian ginseng; ginkgo; ginger; population pharmacokinetic-pharmacodynamic modeling;
D O I
10.1177/0091270006292124
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Systematic evidence regarding herb-drug interactions is lacking. This study investigated herb-drug interactions with warfarin. S-warfarin concentration and response (prothrombin complex activity) data from healthy subjects (n = 24) who received a single warfarin dose (25 mg) and either St John's wort, Asian ginseng, Ginkgo biloba, or ginger were analyzed using a population pharmacokinetic-pharmacodynamic modeling approach. The ratio of S-warfarin apparent clearance (CL/F) compared to control was 1.39 +/- 0.06 and 1.14 +/- 0.04 after St John's wort and Asian ginseng pretreatment, respectively. Other pharmacokinetic and pharmacodynamic parameters were unaffected. Coadministration of St John's wort significantly increased S-warfarin CL/F whereas treatment with Asian ginseng produced only a moderate increase in CLIFF Ginkgo and ginger did not affect the pharmacokinetics of warfarin in healthy subjects. None of the herbs studied had a direct effect on warfarin pharmacodynamics. Studies in anticoagulated patients are warranted to assess the clinical significance of these herb-drug interactions.
引用
收藏
页码:1370 / 1378
页数:9
相关论文
共 41 条
[1]   The integration of pharmacokinetics and pharmacodynamics: Understanding dose-response [J].
Abdel-Rahman, SM ;
Kauffman, RE .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2004, 44 :111-136
[2]   Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients [J].
Anderson, BJ ;
McKee, AD ;
Holford, NHG .
CLINICAL PHARMACOKINETICS, 1997, 33 (05) :313-327
[3]  
[Anonymous], 2000, HERBAL MED EXPANDED
[4]  
Biber A, 2003, PHARMACOPSYCHIATRY, V36, pS32
[5]   Clinical pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development: The capecitabine experience [J].
Blesch, KS ;
Gieschke, R ;
Tsukamoto, Y ;
Reigner, BG ;
Burger, HU ;
Steimer, JL .
INVESTIGATIONAL NEW DRUGS, 2003, 21 (02) :195-223
[6]  
Boeckmann AJ, 1994, NONMEM USERS GUIDE
[7]   A population pharmacokinetic model for docetaxel (Taxotere(R)): Model building and validation [J].
Bruno, R ;
Vivier, N ;
Vergniol, JC ;
DePhillips, SL ;
Montay, G ;
Sheiner, LB .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1996, 24 (02) :153-172
[8]   STEREOCHEMICAL ASPECTS OF WARFARIN DRUG-INTERACTIONS - USE OF A COMBINED PHARMACOKINETIC-PHARMACODYNAMIC MODEL [J].
CHAN, E ;
MCLACHLAN, A ;
OREILLY, R ;
ROWLAND, M .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (03) :286-294
[9]   Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor [J].
Chen, YP ;
Ferguson, SS ;
Negishi, M ;
Goldstein, JA .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 308 (02) :495-501
[10]   Herb-drug interactions: An evidence based approach [J].
Coxeter, PD ;
McLachlan, AJ ;
Duke, CC ;
Roufogalis, BD .
CURRENT MEDICINAL CHEMISTRY, 2004, 11 (11) :1513-1525